TLR3 and neoplasm: Most studies have reported that the activation of TLR3 has an inhibitory effect on tumors and can promote tumor cell apoptosis [12], which may be mainly related to the production of type I interferons and natural killer cells, and the activation of immune cells, such as natural killer cells, dendritic cells, and macrophages [13,14] Thus, TLR3 agonists can be used as immune adjuvants to treat tumors.